Will Atossa CEO’s Recent Opinion Push the Demand For the Stock To Rise Up?

Dr. Steven Quay, the CEO of Atossa Therapeutics (ATOS) just recently shared his point of view on the lab origin of COVID-19.

Even on YouTube, the CEO provides an elaborated explanation about several facts of that origin from Wuhan’s lab. He somehow suspects that the Wuhan Institute of Virology and Wuhan Centers for Disease Control (CDC). Sending the open letter to WHO creates a serious decision for him to proceed with investigation requests from the organization.

Related:  Eastman Kodak (KODK) recovering to get $33.20 on more than 100 million shares

However, the Chinese authorities have already lost a chance to contain the elements of evidence that the virus really came out from those places of Wuhan. So many things changed since the coronavirus breakout. Anyway, that’s not a major problem for regular traders who are hungry for high-return bringing stocks. Perhaps, the letter of Dr. Steven Quay will lift the demand for Atossa shares up significantly since he is from the authentic community of virologists and biotech experts.

Anthony Gonzales

Biotech, Tech, and Crypto reporter Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.